Zhitong Finance App News, Cornerstone Pharmaceutical-B (02616) announced that the clinical research results of CS2009 (PD-1/VEGF/CTLA-4 three specific antibodies), one of the company's core assets, were successfully selected for the 2026 European Society of Medical Oncology (ESMO) annual meeting, and will be presented in the form of two quick oral reports, covering CS2009 phase I/II clinical trial data in patients with advanced non-small cell lung cancer (NSCLC) and metastatic colorectal cancer (mCRC).

Currently, the title of the relevant abstract has been published on ESMO's official website. It should be clarified that the data presented in the summary is only up to April 2026 and is intended to meet the requirements of the conference submission deadline. Cornerstone Pharmaceuticals will present clinical research results closer to the data deadline at the ESMO annual conference to be held in Madrid, Spain from October 23 to 26, 2026.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.